Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H, Hiraishi T, Kobayashi M, Yasuda K, Yamamoto H, Yasuda H, Kurosaki M, Izumi N, Yotsuyanagi H, Suzuki M, Itoh F.
Ikeda H, et al. Among authors: matsunaga k.
J Med Virol. 2017 Jan;89(1):99-105. doi: 10.1002/jmv.24608. Epub 2016 Jul 6.
J Med Virol. 2017.
PMID: 27329864